DUBLIN--(BUSINESS WIRE)--The "Pneumonia Drug Development Pipeline Review, 2017" report has been added to Research and Markets' offering.
The report,"Pneumonia Drug Development Pipeline Review, 2017" provides an overview of the pneumonia pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Community Acquired Pneumonia, Hospital Acquired Pneumonia and Ventilator Associated Pneumonia and features dormant and discontinued projects.
Scope
- Which companies are the most active within the pipeline for pneumonia therapeutics?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in the field of pneumonia?
Key Topics Covered:
1 Table of Contents
2 Introduction
3 Therapeutics Development
4 Therapeutics Assessment
5 Companies Involved in Therapeutics Development
6 Dormant Projects
7 Discontinued Products
8 Product Development Milestones
9 Appendix
Companies Mentioned
- Achaogen Inc
- Adenium Biotech ApS
- Aridis Pharmaceuticals LLC
- AstraZeneca Plc
- Bayer AG
- Biotest AG
- Cardeas Pharma Corp
- Destiny Pharma Ltd
- Dong-A Socio Holdings Co Ltd
- InflaRx GmbH
- ioGenetics Inc
- Kyorin Pharmaceutical Co Ltd
- Lakewood-Amedex Inc
- MedImmune LLC
- Meiji Seika Pharma Co Ltd
- Melinta Therapeutics Inc
- Merck & Co Inc
- Motif Bio Plc
- Nabriva Therapeutics AG
- Paratek Pharmaceuticals Inc
- Polyphor Ltd
- Sealife PHARMA GMBH
- Shionogi & Co Ltd
- TaiGen Biotechnology Co Ltd
- Takeda Pharmaceutical Company Ltd
- Tetraphase Pharmaceuticals Inc
- The Medicines Company
- Theravance Biopharma Inc
- TiGenix NV
- Wockhardt Ltd
- Zavante Therapeutics Inc
For more information about this report visit https://www.researchandmarkets.com/research/dmrlq8/pneumonia_drug
